Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 8:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HBP Clear all
Completed Not applicable Interventional Results available

Scripps Wired for Health Monitoring Study

NCT01975428
View directory record Official record
Conditions
Diabetes, Hypertension, Cardiac Arrhythmia
Interventions
DM Pgm + device, Control
Device · Behavioral
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Jun 26, 2026, 8:43 AM EDT
Enrolling by invitation Not applicable Interventional

Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle

NCT06002165
View directory record Official record
Conditions
Pregnancy Related, Hypertension
Interventions
Usual Care, ACHIEVE Multi-component Implementation Strategy
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
0 Years to 99 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jun 26, 2026, 8:43 AM EDT
Not yet recruiting Phase 2 Interventional

Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

NCT07473700
View directory record Official record
Conditions
Hypertension, Pulmonary, Lung Diseases, Interstitial
Interventions
TX000045
Drug
Lead sponsor
Tectonic Operating Company, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jun 26, 2026, 8:43 AM EDT
Completed Not applicable Interventional Results available

Reducing Disparities in the Treatment of Hypertension Using the OWL mHealth Tool

NCT03974334
View directory record Official record
Conditions
Hypertension
Interventions
OWL-Hypertension 8 Wk Trial
Behavioral
Lead sponsor
Paula Gardiner
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Jun 26, 2026, 8:43 AM EDT
Terminated Not applicable Interventional

Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin

NCT04784234
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
GlaucoCetin, Placebo
Dietary Supplement · Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jun 26, 2026, 8:43 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients

NCT01502787
View directory record Official record
Conditions
Hypertension
Interventions
Metoprolol succinate, Nebivolol, Forearm blood flow, Microneurography, Rhythmic handgrip exercise, Lower body negative pressure, Angiotensin II
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced Jun 26, 2026, 8:43 AM EDT
Completed Phase 4 Interventional

Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide

NCT04231084
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Vasodilator testing (Inhaled Nitric Oxide), Vasodilator testing (Inhaled Epoprostenol)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jun 26, 2026, 8:43 AM EDT
Completed No phase listed Observational

Thromboelastogram in Postdelivery Preeclamptic Patients

NCT03555630
View directory record Official record
Conditions
Preeclampsia, Coagulation Disorder, Pregnancy Complications
Interventions
Thromboelastogram
Diagnostic Test
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Jun 26, 2026, 8:43 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

: Vascular Function in Health and Disease

NCT02966665
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions
Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4
Other · Drug
Lead sponsor
Russell Richardson
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Jun 26, 2026, 8:43 AM EDT
Completed Phase 3 Interventional

ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)

NCT00091598
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
44
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2010 · Synced Jun 26, 2026, 8:43 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Pulmonary Vascular Disease Phenomics Program PVDOMICS

NCT02980887
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
No Intervention
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
1,195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2029
U.S. locations
7
States / cities
Tucson, Arizona • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Jun 26, 2026, 8:43 AM EDT
Completed Phase 2 Interventional

Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)

NCT01965106
View directory record Official record
Conditions
Glaucoma, Angle-closure, Primary, Acute
Interventions
QPI-1007 Injection, (including placebo)
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Orange, California • Pasadena, California • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Jun 26, 2026, 8:43 AM EDT
Active, not recruiting Not applicable Interventional

Remote Monitoring and Virtual Collaborative Care For Hypertension Control to Prevent Cognitive Decline Phase II

NCT05138601
View directory record Official record
Conditions
Hypertension
Interventions
Virtual Collaborative Care Clinic
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Kansas City, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jun 26, 2026, 8:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients

NCT00952081
View directory record Official record
Conditions
Hypertension, Brain Tumor, Epilepsy
Interventions
Clevidipine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2015 · Synced Jun 26, 2026, 8:43 AM EDT
Suspended Phase 4 Interventional

Ketamine for Sedation in Severe Traumatic Brain Injury

NCT06429657
View directory record Official record
Conditions
Severe Traumatic Brain Injury, Intracranial Hypertension, Intracranial Hemorrhage, Hypertensive
Interventions
Ketamine with propofol, Standard of Care propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam
Drug · Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Jun 26, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Guidelines for Drug Therapy of Hypertension: Multi-Site Implementation

NCT00122161
View directory record Official record
Conditions
Hypertension
Interventions
ATHENA Decision Support System, An Automated Clinical Decision Support System for Health Care Providers, Profiling performance
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
3
States / cities
Palo Alto, California • San Francisco, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Jun 26, 2026, 8:43 AM EDT
Recruiting Not applicable Interventional

Treatment of Supine Hypertension in Autonomic Failure (CPAP)

NCT03312556
View directory record Official record
Conditions
Supine Hypertension, Autonomic Failure
Interventions
continuous positive airway pressure (CPAP), Placebo
Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jun 26, 2026, 8:43 AM EDT
Recruiting Phase 1 Interventional

A Study of LY3971297 in Healthy Participants

NCT06148272
View directory record Official record
Conditions
Healthy, Obesity, Hypertension
Interventions
LY3971297, Placebo, LY3971297 IV
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jun 26, 2026, 8:43 AM EDT
Terminated Phase 4 Interventional Results available

Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study

NCT01275339
View directory record Official record
Conditions
Aortic Stenosis, LV Remodeling, Hypertrophy
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Jun 26, 2026, 8:43 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution

NCT06120842
View directory record Official record
Conditions
Cataract, Glaucoma, Ocular Hypertension
Interventions
Bimatoprost Implant System (High Dose), Bimatoprost Implant System (Low Dose), Timolol Maleate Ophthalmic Solution, 0.5%, Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL, SpyGlass IOL
Drug · Device
Lead sponsor
SpyGlass Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Glendale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Jun 26, 2026, 8:43 AM EDT
Recruiting Not applicable Interventional

Reach Out 2: Emergency Department-Initiated Hypertension Mobile Health Intervention Connecting Multiple Health Systems

NCT06391073
View directory record Official record
Conditions
Hypertension
Interventions
Self-Measured Blood Pressure Monitoring, Physician appointment and transportation scheduling
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 99 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Jun 26, 2026, 8:43 AM EDT
Completed Phase 4 Interventional Results available

Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension

NCT02489045
View directory record Official record
Conditions
Liver Diseases, Portal Hypertension
Interventions
SHAPE measurement (Sonazoid ultrasoud contrast agent)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
21 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Jun 26, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension

NCT02279745
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ralinepag
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Jun 26, 2026, 8:43 AM EDT
Terminated Phase 2 Interventional Results available

Mechanisms of EPO-induced Hypertension

NCT03810911
View directory record Official record
Conditions
Chronic Kidney Disease, Blood Pressure, Anemia
Interventions
Darbepoetin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jun 26, 2026, 8:43 AM EDT